• Global resolution secures patient access to Sandoz biosimilar Hyrimoz^® (adalimumab)[1] for the reference medicine Humira^®**
• Resolution paves way for 2018 launch in key European markets and secures US market entry planned in 2023

Holzkirchen, October 11, 2018 – Sandoz, a Novartis division and the global leader in biosimilars, today announced a global resolution of all intellectual property (IP) related litigation with AbbVie concerning the proposed Sandoz biosimilar Hyrimoz^® (adalimumab)[1] for …

• Despite major advances in modern medicine, universal access to healthcare remains the largest unmet medical need
• Building on the inaugural Sandoz HACk, this year’s competition expands to seek broader digital solutions to local healthcare access challenges
• Three shortlisted entrants will attend South by Southwest (SXSW), where Sandoz will work with them to create scalable solutions that could improve people’s lives

Holzkirchen, October 4, 2018 – Sandoz, the Novartis generics and biosimilars division, today …

• Positive opinion is based on comprehensive data confirming that Sandoz biosimilar pegfilgrastim matches the reference medicine in terms of safety, efficacy and quality
• Sandoz seeks approval in the same indication as the reference medicine, to reduce the duration of neutropenia and the incidence of febrile neutropenia due to chemotherapy, some of the most serious side effects of cancer chemotherapy[1]
• Sandoz is the global leader in biosimilars and continues to improve patient access and support sustainable healthcare with seven …

• Novartis to focus Sandoz division in US on higher growth areas and will sell selected portions of the Sandoz US portfolio to Aurobindo Pharma USA Inc.
   
• Agreement comprises the Sandoz US generic oral solids and Sandoz US dermatology businesses with approximately 300 products and H1 2018 sales of USD 0.6 billion
   
• Transaction supports the Sandoz strategy of focusing on complex generics, value-added medicines and biosimilars to achieve sustainable and profitable growth in the US

Basel, September 6, 2018 – Novartis …

• Biosimilar Hyrimoz^® (adalimumab) approved for use in all same indications as reference medicine*** including rheumatology, gastroenterology and dermatology
• Early therapeutic intervention is essential in rheumatoid arthritis, supporting urgency of treatments like Hyrimoz
• Fourth Sandoz biosimilar approved in Europe** in past 18 months, and seventh in total, underscoring Sandoz commitment to making access happen through a robust portfolio

Holzkirchen, July 27, 2018 – Sandoz, a Novartis division …